menu
    • menu
    [{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Parathyroid Hormone","moa":"Parathyroid hormone receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Parathyroid Hormone

    Menu

    Parathyroid Hormone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Takeda Pharmaceutical

                            Japan arrow
                            The MedTech Conference
                            Not Confirmed

                            Takeda Pharmaceutical

                            Japan arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Parathyroid Hormone

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Takeda Provides NATPARA Regulatory Update

                            Details : The CRL indicates that the FDA has completed its review of the NATPARA, is a prescription parathyroid hormone PAS and determined that it cannot be approved in its present form.

                            Product Name : Natpara

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            March 22, 2022

                            Lead Product(s) : Parathyroid Hormone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University of Aarhus

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            University of Aarhus

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Parathyroid Hormone

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Takeda Pharmaceutical | Aarhus University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment With PTH After Sternotomy in Cardiac Surgery Patients

                            Details : Parathyroid Hormone is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            November 08, 2011

                            Lead Product(s) : Parathyroid Hormone

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Takeda Pharmaceutical | Aarhus University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Columbia University

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Columbia University

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Parathyroid Hormone

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : NPS PHARMS INC | SHIRE PLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism

                            Details : Parathyroid Hormone is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypoparathyroidism.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            September 13, 2010

                            Lead Product(s) : Parathyroid Hormone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : NPS PHARMS INC | SHIRE PLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth